about
Electron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial BioenergeticsModeling Huntington's disease with induced pluripotent stem cellsImpaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtinRole of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesisImpaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions.Structural characterization of plasma metabolites detected via LC-electrochemical coulometric array using LC-UV fractionation, MS, and NMR.Study of plasma-derived miRNAs mimic differences in Huntington's disease brain.Oxidative stress and DNA damage in patients with migraine.8OHdG is not a biomarker for Huntington disease state or progressionHTRF analysis of soluble huntingtin in PHAROS PBMCs.A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases.Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.Potential biomarkers to follow the progression and treatment response of Huntington's disease.Oxidative Stress and Huntington's Disease: The Good, The Bad, and The Ugly.Antioxidant gene therapy against neuronal cell death.PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease.Antioxidative defense mechanisms controlled by Nrf2: state-of-the-art and clinical perspectives in neurodegenerative diseases.Riboflavin Has Neuroprotective Potential: Focus on Parkinson's Disease and Migraine.Evaluation of oxidative metabolism and oxidative DNA damage in patients with obsessive-compulsive disorder.8-OHdG: its (limited) potential as a biomarker for Huntington's disease.Peripheral biomarkers of oxidative stress and their limited potential in evaluation of clinical features of Huntington's patients.Behavioural profile of Wistar rats with unilateral striatal lesion by quinolinic acid (animal model of Huntington disease) post-injection of apomorphine and exposure to static magnetic field.Selective A2A receptor antagonist SCH 58261 modulates striatal oxidative stress and alleviates toxicity induced by 3-Nitropropionic acid in male Wistar rats.A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.
P2860
Q26795417-A71EE1F6-A055-4FFC-A556-ACEA53005CCFQ27004209-B37C9D05-C99A-449D-9B29-CEEE10D82C9EQ27312215-C3D06C6E-D763-4783-8609-5E612A4EF010Q28386202-2C406412-EDAA-4550-9504-943D0856B7A8Q34153434-8D030A9D-8A7F-47D6-A9A8-FED742DE83E1Q36412924-E6EB72C8-FCC2-4753-9513-C1FC43DBB931Q36469923-8764B917-41C4-445E-89D7-DBFE9D9E8CA1Q36586584-E289CF95-D098-4F06-86C5-F4190BDE8D6BQ37027144-94CCACB8-39AE-471E-BE85-5657DD804BE4Q37227046-9EFC70E0-7797-46CB-93B8-B2715E9B92D9Q37323166-247D5A4F-5EDC-4E6D-949A-FB084E8D861FQ37368003-6B529F8B-9618-4BED-8BE4-A4D359C2A648Q37415254-48629187-5D4E-4A09-B51B-28F93CCDE115Q37643688-D38CEB6F-B4C1-4065-A546-A9A4248402DEQ37647941-C27F2E56-27E3-4441-9251-2471754FEB69Q37648786-31E37E99-49C8-46E5-A4EE-A72EB8148A82Q38244092-CA53A6FB-E0DB-448F-9168-FB54FFC7C7B5Q38647109-5CDA64AB-AE86-4EB0-BDE7-66D7A7E526AEQ40520719-6B3392FC-6095-4DAC-87E9-46933F10C01AQ45291073-83E7884B-EF3C-41AE-9C64-32DDB50AE88EQ45299998-D87D275F-182A-4DC6-885B-2FFF88935927Q45304164-C73590D9-890D-44D3-A241-88C5E5135F64Q46323118-99526651-CD7F-4B69-B31E-8E04D01DF37AQ52721984-C55E3DB4-6910-4929-8658-861318D33FC5
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 March 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
8OHdG as a marker for Huntington disease progression
@en
8OHdG as a marker for Huntington disease progression.
@nl
type
label
8OHdG as a marker for Huntington disease progression
@en
8OHdG as a marker for Huntington disease progression.
@nl
prefLabel
8OHdG as a marker for Huntington disease progression
@en
8OHdG as a marker for Huntington disease progression.
@nl
P2093
P2860
P50
P1476
8OHdG as a marker for Huntington disease progression
@en
P2093
Andrew R Juhl
PREDICT-HD Investigators and Coordinators of the Huntington Study Group
Wayne R Matson
P2860
P304
P356
10.1016/J.NBD.2012.02.012
P577
2012-03-05T00:00:00Z